Status:

COMPLETED

Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection

Lead Sponsor:

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Collaborating Sponsors:

AbbVie

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions:

Hepatitis C Infection

HIV Infection

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this study was to assess the efficacy of a fixed dose combination (FDC) of glecaprevir/pibrentasvir (G/P) given for 4 weeks for treatment of acute hepatitis C (HCV), with or without HIV...

Detailed Description

The study was conducted in two steps. In Step 1, participants received four weeks of treatment with G/P for acute HCV infection and were then followed 24 weeks post treatment. Participants with HCV re...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Acute HCV infection (or reinfection) within 24 weeks prior to entry
  • Detectable HCV RNA at the screening visit
  • Exclusion Criteria
  • Any HCV treatment during the current acute HCV infection episode
  • Known preexisting cirrhosis
  • Acute HIV-1 infection
  • Presence of active or acute AIDS-defining opportunistic infections, active serious infection (other than HIV-1 or HCV), active hepatitis B virus (HBV) or active hepatitis A virus (HAV)
  • Chronic use of systemically administered immunosuppressive agents
  • History of solid organ transplantation
  • History of conditions that could interfere with the absorption of the study drug
  • Concurrent use of prohibited medications
  • Known hypersensitivity to glecaprevir or pibrentasvir, the metabolites, or parts of the formulation
  • Females who are pregnant or breastfeeding
  • Males with pregnant female partner

Exclusion

    Key Trial Info

    Start Date :

    November 20 2019

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    August 22 2023

    Estimated Enrollment :

    45 Patients enrolled

    Trial Details

    Trial ID

    NCT04042740

    Start Date

    November 20 2019

    End Date

    August 22 2023

    Last Update

    July 11 2024

    Active Locations (12)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 3 (12 locations)

    1

    Ucsd, Avrc Crs (701)

    San Diego, California, United States, 92103

    2

    University of California, San Francisco HIV/AIDS CRS (801)

    San Francisco, California, United States, 94110

    3

    University of Colorado Hospital CRS (6101)

    Aurora, Colorado, United States, 80045

    4

    Whitman-Walker Institute, Inc. CRS (31791)

    Washington D.C., District of Columbia, United States, 20005